SEC 13F Intelligence

Managers / Q3 2021 · view latest →

Rock Springs Capital Management LP

CIK 0001595725 · 650 SOUTH EXETER STREET, SUITE 1070, BALTIMORE, MD, 21202 · 4102200129

Reported Value
$4.8B
Q3 2021
Positions
153
Filings on Record
30
2019–present window
Filed
Nov 15, 2021
original filing

Summary

Rock Springs Capital Management LP reported $4.8B in U.S.-listed holdings across 153 positions for Q3 2021.

Its largest position, Agilon Health, represents 3.9% of the portfolio.

Compared with Q2 2021, the fund opened 11 new positions and exited 14.

Portfolio Metrics

Turnover
+12.4%
vs prior filed quarter
Top-10 Concentration
+26.3%
share of reported value
Largest Position
+3.9%
Agilon Health
New / Exited
11 / 14
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $2.1BQ4 ’18Q1 ’19: $2.6BQ2 ’19: $2.8BQ3 ’19: $2.5BQ4 ’19: $3.2BQ4 ’19Q1 ’20: $2.4BQ2 ’20: $3.6BQ3 ’20: $3.9BQ4 ’20: $4.7BQ4 ’20Q1 ’21: $4.6BQ2 ’21: $5.1BQ3 ’21: $4.8BQ4 ’21: $4.3BQ4 ’21Q1 ’22: $4.0BQ2 ’22: $3.4BQ3 ’22: $3.9BQ4 ’22: $4.2BQ4 ’22Q1 ’23: $4.2BQ2 ’23: $4.2BQ3 ’23: $3.7BQ4 ’23: $4.1BQ4 ’23Q1 ’24: $3.9BQ2 ’24: $3.3BQ3 ’24: $3.1BQ4 ’24: $2.6BQ4 ’24Q1 ’25: $1.7BQ2 ’25: $1.6BQ3 ’25: $1.7BQ4 ’25: $2.0BQ4 ’25Q1 ’26: $1.7Bfilingsflow.com

Portfolio Composition

By security type
Common Stock: 75.0%Other: 16.7%ADR: 7.2%US DOMESTIC: 1.1%Equity WRT: 0.0%
  • Common Stock · 75.0% · $3.6B
  • Other · 16.7% · $793M
  • ADR · 7.2% · $343M
  • US DOMESTIC · 1.1% · $54M
  • Equity WRT · 0.0% · $343,000

Quarter-over-Quarter Changes full breakdown →

vs Q2 2021 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
BAXBAXTER INTL INCNEW+450.0K450.0K+$36M$36M
WRBYWARBY PARKER INCNEW+650.0K650.0K+$34M$34M
IMRXIMMUNEERING CORPNEW+1.09M1.09M+$29M$29M
ABOSACUMEN PHARMACEUTICALS INCNEW+1.58M1.58M+$23M$23M
WHWKAADI BIOSCIENCES INCNEW+764.7K764.7K+$22M$22M
ICOSAVAX INCNEW+734.2K734.2K+$22M$22M
AMRYT PHARMA PLCNEW+1.30M1.30M+$16M$16M
LEAP THERAPEUTICS INCNEW+3.51M3.51M+$14M$14M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q3 2021

50 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1AGILON HEALTH INCCOM3.90%$185M7.08M
2HUMHUMANA INChistory →COM2.80%$133M342.0K
3AFWALIGN TECHNOLOGY INChistory →COM2.80%$133M200.0K
4PODDINSULET CORPhistory →COM2.62%$124M437.6K
5ISRGINTUITIVE SURGICAL INChistory →COM NEW2.51%$119M120.0K
6AGIOAGIOS PHARMACEUTICALS INChistory →COM2.48%$118M2.56M
7ZLABZAI LAB LTDhistory →ADR2.39%$114M1.08M
8IDXXIDEXX LABS INChistory →COM2.35%$112M180.0K
9HCAHCA HEALTHCARE INChistory →COM2.30%$109M450.0K
10NBIXNEUROCRINE BIOSCIENCES INChistory →COM2.12%$101M1.05M
11ARGXARGENX SEhistory →SPONSORED ADR2.00%$95M315.0K
12NVV1NOVAVAX INChistory →COM NEW1.98%$94M455.0K
13UNHUNITEDHEALTH GROUP INChistory →COM1.97%$94M240.0K
14IMCRIMMUNOCORE HLDGS PLChistory →ADS1.91%$91M2.45M
152655787DBLUEPRINT MEDICINES CORPhistory →COM1.84%$87M849.7K
16HORIZON THERAPEUTICS PUB LSHS1.62%$77M702.0K
17FRPTFRESHPET INChistory →COM1.58%$75M527.0K
18INVITAE CORPCOM1.56%$74M2.61M
19NVROEURNEVRO CORPhistory →COM1.56%$74M635.7K
20RAREULTRAGENYX PHARMACEUTICAL INhistory →COM1.52%$72M801.1K
21ACRSACLARIS THERAPEUTICS INChistory →COM1.44%$68M3.80M
22EWEDWARDS LIFESCIENCES CORPhistory →COM1.39%$66M582.0K
23ASCENDIS PHARMA A/SSPONSORED ADR1.34%$64M400.0K
24MRTXEURMIRATI THERAPEUTICS INChistory →COM1.31%$63M353.5K
25PHRPHREESIA INChistory →COM1.26%$60M970.0K
26ALNYALNYLAM PHARMACEUTICALS INChistory →COM1.23%$59M311.0K
27EVHEVOLENT HEALTH INChistory →CL A1.22%$58M1.88M
28PCRXPACIRA BIOSCIENCES INChistory →COM1.18%$56M1.00M
29EXKEXACT SCIENCES CORPhistory →COM1.14%$54M570.0K
30PROTHENA CORP PLCSHS1.06%$51M710.4K
31TFXTELEFLEX INCORPORATEDhistory →COM1.03%$49M130.0K
32KARUNA THERAPEUTICS INCCOM1.01%$48M391.9K
33ARVNARVINAS INChistory →COM1.00%$47M577.5K
34CEREVEL THERAPEUTICS HLDNG ICOM0.99%$47M1.60M
35SWAVUSDSHOCKWAVE MED INChistory →COM0.95%$45M220.0K
36ACHCACADIA HEALTHCARE COMPANY INhistory →COM0.95%$45M710.0K
37VERVE THERAPEUTICS INCCOM0.95%$45M962.8K
38KYMRKYMERA THERAPEUTICS INChistory →COM0.91%$43M732.9K
39HCATHEALTH CATALYST INChistory →COM0.89%$43M850.0K
40SGENUSDSEAGEN INChistory →COM0.89%$42M250.0K
41PENPENUMBRA INChistory →COM0.83%$39M147.5K
42ACCDUSDACCOLADE INChistory →COM0.82%$39M923.0K
43EHCENCOMPASS HEALTH CORPhistory →COM0.79%$38M500.0K
44TVTXTRAVERE THERAPEUTICS INChistory →COM0.76%$36M1.50M
45BAXBAXTER INTL INChistory →COM0.76%$36M450.0K
46WRBYWARBY PARKER INChistory →CL A COM0.73%$34M650.0K
47GRPHGRAPHITE BIO INChistory →COM0.72%$34M2.08M
48XENTEURINTERSECT ENT INChistory →COM0.70%$33M1.22M
49SRPTSAREPTA THERAPEUTICS INChistory →COM0.68%$32M350.0K
50ALLKGUSDALLAKOS INChistory →COM0.68%$32M305.7K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$1.7B100May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$2.0B99Feb 17, 202613F-HRchanges · EDGAR ↗
Q3 2025$1.7B93Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$1.6B93Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$1.7B96May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$2.6B107Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$3.1B109Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$3.3B112Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$3.9B114May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$4.1B104Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$3.7B120Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$4.2B123Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$4.2B121May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$4.2B120Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$3.9B128Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$3.4B131Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$4.0B135May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$4.3B136Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$4.8B153Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$5.1B156Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$4.6B151May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$4.7B155Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$3.9B148Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$3.6B143Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$2.4B131May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$3.2B130Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$2.5B138Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$2.8B135Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$2.6B131May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$2.1B133Feb 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.